Meso Scale Discovery®

Eve Technologies has partnered with Meso Scale Discovery® by expanding our assay services to connect our clients with the benefits of the MSD® Platform. In doing so, we are continuing the pursuit of our mandate to facilitate and advance biomedical research. The addition of the MSD® technology platform to Eve Technologies promises next-level accuracy and sensitivity for your research. With the benefits of MSD®’s technology platform, doors are being opened to new discoveries and breakthroughs.

Renowned for exceptional sensitivity that offers detection limits in the femtogram range, The Meso Scale Discovery® S-PLEX® assay platform is significantly enhancing immunoassay sensitivity compared to alternative platforms such as Luminex® and ELISA.

Discover the power of our MSD® Discovery Assays®. Being pre-configured for quantifying single or multiple targets within a single, small-volume sample, Eve Technologies offers its unique and flexible purchase model based on the required number of wells. As with all our Discovery Assays®, we ensure cost-effectiveness for our valued partners in both academia and the biomedical / drug discovery industry. Collaborate with us to unlock new possibilities in your research endeavors!

Benefits and Applications of MSD® Assays:

• Exceptional Sensitivity: MSD® assays detect analytes at very low concentrations, often in the femtogram/mL range. This sensitivity is crucial for identifying low-abundance biomarkers that other platforms might miss.

• High Precision: These assays offer minimal background noise and superior signal-to-noise ratios, ensuring reliable and reproducible results even in complex sample matrices. This precision is vital for accurate quantification in both research and diagnostic applications.

• Multiplexing Capability: While not as extensive as the Multiplexing LASER Bead Technology platform, MSD® can still detect multiple analytes in a single sample. This enhances throughput, reduces sample volume requirements, and conserves valuable samples, making it ideal for comprehensive biomarker profiling.

• Versatile Applications: MSD® supports various applications, including biomarker discovery, drug development, therapeutic monitoring, and basic research. Its flexibility allows researchers to tailor assays to specific needs, facilitating a broad spectrum of scientific inquiries, such as custom anti-drug antibody assays (ADA) and pharmacokinetics (PK) studies.

• Cost-Effectiveness: Eve Technologies’ Discovery Assays® make select MSD® assays cost-effective by offering flexible purchase models based on the required number of wells. This ensures that the MSD® technology platform fits a wide range of research budgets.

• Streamlined Workflow: Despite the complexity of MSD® assays, the platform is efficient in analysis and data generation. Partnering with Eve Technologies means we handle the assay challenges and provide your results within industry-leading turnaround times.

Discovery Assays

Human MSD® Discovery Assay® pTau217

$67.98

Ultrasensitive assay that measures phosphorylated Tau at threonine 217 (pTau217) in a single-analyte format. 

Monitoring pTau217 holds potential for early detection, prognosis, and therapeutic development in neurodegenerative diseases characterized by Tau pathology and is emerging as a promising biomarker for Alzheimer’s disease (AD) diagnosis and monitoring disease progression.  Elevated levels of pTau217 have also been linked to other tauopathies, such as frontotemporal dementia and progressive supranuclear palsy (with varying degrees of specificity).

Human MSD® Discovery Assay® Neurology 3-Plex Panel 1

$98.16

Ultrasensitive assay that measures 3 biomarkers associated with neurological and neurodegenerative diseases: Glial Fibrillary Acidic Protein (GFAP), Neurofilament L (NF-L), all forms of Tau (Tau (total)) 

Elevated levels of these biomarkers have been associated with various neurological conditions, particularly those involving neuronal/brain injury (concussion), traumatic brain injury (TBI), neurodegeneration, or neuroinflammation, such as stroke, multiple sclerosis (MS), and neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), Motor neurone disease (MND) and the most common form of MND, amyotrophic lateral sclerosis (ALS).  Elevated Tau levels in CSF are also observed in other tauopathies, such as frontotemporal dementia and progressive supranuclear palsy.

Measurement of GFAP, NF-L, and Tau (total) levels holds promise for diagnosing, monitoring disease progression, and assessing treatment efficacy.

Human MSD® Discovery Assay® ULTRA HIGH Sensitivity Cytokine Array

$82.19

Ultrasensitive assay that simultaneously measures 9 biomarkers associated with the inflammation response and immune system regulation:
IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17A, TNF-α 

Consider this assay for samples with delicate concentration trends in the femtogram range and limited sample volumes with picogram-level expectations. The finely tuned detection capabilities allow you to dilute your samples without losing sensitivity. This guarantees accurate results, no matter the volume constraints.

Are you interested in learning about Discovery Assays and how they can benefit your research?

Learn More About Discovery Assays

---

Custom Plex Assay

Meso Scale Discovery® Custom-Plex Assays are available upon request, offering over 800 markers on this platform. Contact our scientists to learn more about our offerings. To discover how Custom-Plex Assays can benefit your research, follow the link below.

Learn More About Custom Assays

---

Contact Our Scientist

If you have any questions or need further assistance, please don’t hesitate to contact our scientist.